A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Last Updated   May 23, 2024 - 21:00

Want to learn how to participate in this trial?


  • Gender
  • Age
    2 - 17 years
  • Phase
    phase 2
    The drug or treatment is given to a larger group of people to see if it is effective and to better understand its safety.
  • Sites
    18 sites
  • Status


The purpose of this study is to determine the effect of nipocalimab on total serum immunoglobulin G (IgG) in pediatric participants 2 to less than (<) 18 years of age (globally) and 8 to <18 years of age (for Unites Stated (US) sites only), the safety and tolerability of treatment with nipocalimab in children and adolescents and to evaluate the pharmacokinetics (PK) of nipocalimab in children and adolescents with generalized myasthenia gravis (gMG) who have an insufficient clinical response to ongoing, stable standard-of-care therapy.


  • Myasthenia Gravis


Inclusion Criteria:

* Age: For US sites only: 8 to <18 years

* Diagnosis of myasthenia gravis (MG) with generalized muscle weakness meeting the clinical criteria for generalized myasthenia gravis (gMG) as defined by the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class IIa/b, IIIa/b, or IVa/b at screening

* Has a positive serologic test for acetylcholine receptor (anti-AChR) antibodies or muscle-specific tyrosine kinase (anti-MuSK) antibodies at screening

* A participant using herbal, naturopathic, traditional Chinese remedies, ayurvedic or nutritional supplements, or medical marijuana (with a doctor's prescription) is eligible if the use of these medications is acceptable to the Investigator. These remedies must remain at a stable dose and regimen throughout the study

* Has sufficient venous access to allow drug administration by infusion and blood sampling as per the protocol

* Participants should have a body weight and body mass index between 5th and 95th percentile for age and sex. Obese participants greater than 95th percentile and underweight participants below 5th percentile may participate following medical clearance

* A female of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) at Screening and a negative urine pregnancy test at Day 1 prior to administration of study intervention

Exclusion Criteria:

* Has a history of severe and/or uncontrolled hepatic (example, viral/alcoholic/ autoimmune hepatitis/ cirrhosis/ and/or metabolic liver disease), gastrointestinal, renal, pulmonary, cardiovascular (including congenital heart diseases), psychiatric, neurological musculoskeletal disorder, any other medical disorder(s) (example, diabetes mellitus), or clinically significant abnormalities in screening laboratory, that might interfere with participant's full participation in the study, and/ or might jeopardize the safety of the participant or the validity of the study results

* Has any confirmed or suspected clinical immunodeficiency syndrome not related to treatment of his/her generalized myasthenia gravis (gMG), or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant

* Has had a thymectomy within 12 months prior to screening, or thymectomy is planned during the Active treatment Phase of the study

* Has shown a previous severe immediate hypersensitivity reaction, such as anaphylaxis to therapeutic proteins (example, monoclonal antibodies)

* Has experienced myocardial infarction, unstable ischemic heart disease, or stroke within 12 weeks of screening



Locations in:
United States, Poland, Netherlands, Japan
Country (4) City or Province (18) Status
United States Ann Arbor, MI C.S. Mott Children's Hospital
United States Aurora, CO Children's Hospital Colorado
United States Lawrence, KS University of Kansas Medical Center
United States Los Angeles, CA Childrens Hospital Los Angeles
United States Palo Alto, CA Lucile Packard Children's Hospital Stanford
United States Philadelphia, PA Childrens Hospital Of Philadelphia
United States Phoenix, AZ Phoenix Children's Hospital
United States Pittsburgh, PA University of Pittsburgh Medical Center
United States San Francisco, CA UCSF Benioff Children's Hospital
United States Tampa, FL University of South Florida Morsani Center for Advanced Healthcare
Poland Gdansk Uniwersyteckie Centrum Kliniczne
Netherlands Leiden Leiden University Medical Center
Japan Azumino-shi, Nagano, 20 Nagano Children's Hospital
Japan Chiba Chiba University Hospital
Japan Miyazaki, 45 University of Miyazaki Hospital
Japan Nishinomiya-Shi, 28 Hyogo College of Medicine Hospital
Japan Saitama shi, 11 Saitama Prefecture Children's Medical Center
Japan Shinjuku-ku, 13 Tokyo Women's Medical University Hospital

Indicates 50+ sites in this region: click to zoom in.


Indicates 10+ sites in this region: click to zoom in.


Indicates < 10 sites in this region: click to zoom in.

Corresponds to individual site.

View Map Legend